

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/227181089>

Periplasmic expression and one-step purification of urease subunit B of *Helicobacter pylori*

Article in *World Journal of Microbiology and Biotechnology* · April 2011

DOI: 10.1007/s11274-010-0540-2

CITATION

1

READS

130

8 authors, including:



Amirhooshang Alvandi

Kermanshah University of Medical Sciences

24 PUBLICATIONS 113 CITATIONS

[SEE PROFILE](#)



Abbas Jolodar

Shahid Chamran University of Ahvaz

46 PUBLICATIONS 395 CITATIONS

[SEE PROFILE](#)



Ehsan Aryan

Mashhad University of Medical Sciences

21 PUBLICATIONS 205 CITATIONS

[SEE PROFILE](#)



Gholipour Abolfazl

Shahrekord University of Medical Sciences

37 PUBLICATIONS 64 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



frequency study of Bacterial Agents and Antibiotic Resistance Pattern in Patients With Ventilator-Associated Pneumonia Hospitalized in Respiratory ICU Imam Reza Hospital, Kermanshah, 2016 [View project](#)



scorpion venom [View project](#)

All content following this page was uploaded by [Abbas Jolodar](#) on 27 March 2015.

The user has requested enhancement of the downloaded file.

Periplasmic expression and one-step purification of urease subunit B of *Helicobacter pylori*

Amirhooshang Alvandi · Ahmad Farajzadeh · Mehri Ghaforian Borojerdnia ·
Abbass Jelodar · Ehsan Aryan · Abolfazl Gholipour ·
Abdolrahim Masjedizadeh · Manoochehr Makvandi

Received: 28 April 2010 / Accepted: 13 August 2010
© Springer Science+Business Media B.V. 2010

Abstract *UreB* is one of the urease subunits of *Helicobacter pylori* and can be used as an excellent antigen candidate for *H. pylori* vaccination. Easy access to highly purified *UreB* protein, facilitate advances in therapeutic or preventive strategies. To achieve a simplified purification procedure, the present report represents a novel method of producing recombinant urease subunit B extracellularly. *ureB* gene from 26,695 standard strain was amplified by PCR and cloned into pET-26b(+) expression vector. *UreB* was expressed as a soluble, N-terminal pelB and C-terminal hexahistidine-tagged fusion protein (*UreB*-6His) and secreted into the periplasmic space of *Escherichia coli*. Expression of the recombinant *UreB* in *E. coli* BL21 (DE3) was induced by isopropylthio- β -D-galactoside (IPTG).

Expression of *UreB* was confirmed by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and western blot analysis using anti-His monoclonal antibody. *UreB*-6His protein was extracted from the periplasm by osmotic shock treatment and was purified in one step by Nickel affinity chromatography. In conclusion, the present protocol is easier to perform; more time effective and low cost than earlier methods.

Keywords *Helicobacter pylori* · Urease subunit B · Cloning · Periplasmic expression

Introduction

Helicobacter pylori causes peptic ulcer disease and some forms of gastric cancer. It is one of the most common chronic bacterial infections of humans (Hatzifoti et al. 2000). The most efficient and economical approach with low risk of adverse reaction to the prevention and control of *H. pylori* infection is vaccination (Del Giudice and Michetti 2004; Rupnow et al. 1999).

Urease and its subunits are currently the most promising vaccine candidates, and their value as vaccine antigens have been confirmed by numerous studies in mice, ferrets, non-human primates and human clinical trials (Cuenca et al. 1996; Del Giudice and Michetti 2004; Ferrero et al. 1994; Haas and Meyer 1997; Stadlander et al. 1996). *UreB* one of the four subunits of urease produced by almost all the isolated strains of *H. pylori*. It has been demonstrated to have the strongest antigenicity in all known proteins of *H. pylori* (Corthesy-Theulaz et al. 1995; Pappo et al. 1995). *ureB* gene, responsible for encoding *UreB* with 569 amino acid residues, is a highly conserved nucleotide sequence with a similarity of approximately 95% in different

A. Alvandi (✉) · A. Farajzadeh · A. Gholipour · M. Makvandi
Department of Medical Microbiology, Faculty of Medicine,
Ahvaz Jundishapur University of Medical Sciences,
61357-15794 Ahvaz, Iran
e-mail: ah_alvandi@yahoo.com

M. Ghaforian Borojerdnia
Department of Immunology, Faculty of Medicine, Ahvaz
Jundishapur University of Medical Sciences, Ahvaz, Iran

A. Jelodar
Department of Microbiology, Faculty of Veterinary,
Shahid-Chamran University, Ahvaz, Iran

E. Aryan
Microbiology and Virology Research Center,
Avicenna Research Center, and Department of Clinical
Bacteriology, Ghaem University Hospital, Mashad University
of Medical Sciences, Mashad, Iran

A. Masjedizadeh
Division of Gastroenterology and Hepatology,
Department of Internal Medicine, Ahvaz Jundishapur University
of Medical Sciences, Ahvaz, Iran

H. pylori isolates (Akada et al. 2000; Labigne et al. 1991). On the other hand, it has been proven that UreB is more protective and safer than subunit A in mice; with no signs of gastritis or other side effects after therapeutic vaccination (Corthesy-Theulaz et al. 1995; Ferrero et al. 1995; Hatzifoti et al. 2004). These data strongly indicate that UreB can be used as an excellent antigen candidate for vaccination against *H. pylori*.

Easy access to highly purified UreB protein by investigators should therefore facilitate advances in therapeutic or preventive strategies. Previous purification methods of native or recombinant urease and its subunits invariably required two or several steps involving conventional size exclusion and cation exchange or FPLC combining cation exchange, size exclusion chromatography, and sometimes the conventional hydrophobic interaction gel (Evans et al. 1991; Turbett et al. 1992).

Recovery of a recombinant gene product can be greatly simplified by a secretion strategy that minimises contamination from host proteins and even in the case of periplasmic translocation, a simple osmotic shock or cell wall permeabilization can be used to obtain the product without the release of cytoplasmic protein contaminants. In addition secretion of recombinant proteins to the periplasmic space of *E. coli* by fusing a signal peptide to the N-terminal residue, have several advantages such as reduction of contamination with endotoxins and DNA, higher product stability, solubility and biological activity and correct folding (Baneyx and Mujacic 2004; Cornelis 2000; Mergulhao et al. 2005; Rastgar Jazii et al. 2007; Shokri et al. 2003). Periplasmic expression has been shown to be beneficial in the production of several recombinant proteins.

In order to simplify the procedure steps and further reduce cost in *H. pylori* vaccine production, the present report represents a novel method of producing recombinant Urease subunit B extracellularly. This method is based on expression of UreB sequence containing a NH₂-terminal pelB signal peptide in *E. coli*. Therefore periplasmic content is released from the bacterial pellet by a simple EDTA-containing buffer and the protein can be chromatographed in a single step by affinity chromatography.

Materials and methods

Bacteria and culture conditions

H. pylori strain 26,695 was used in this study grown on Brucella agar supplemented with 10% (v/v) defibrinated sheep blood, containing vancomycin (10 µg ml⁻¹), trimethoprim (5 µg ml⁻¹) and amphotericin B (2 µg ml⁻¹) at 37°C under microaerophilic conditions for 3 days. *E. coli* DH5α was grown at 37°C in Luria-Bertani medium

(Invitrogen, USA) used for molecular biology manipulations and for maintenance of recombinant plasmid DNA. *E. coli* BL21 (DE3) (Novagen, USA) was used for 6-His-tagged fusion peptide expression was grown at 37°C in LB medium.

Designing of primers

ureB nucleotide sequence of *H. pylori* strain 26,695 (GenBank accession number AF507994) was retrieved from the NCBI GenBank (NCBI). Primers were designed with restriction enzyme sites using DNASIS 2.6 software. The stop codon was excluded in designing the reverse primer.

Construction of expression vector

Whole-cell DNA from *H. pylori* strain 26,695 was extracted by Genomic Extraction Kit (MBI Fermentas, Lithuania) according to the manufacturer's procedure. *ureB* was amplified by the PCR using the following oligonucleotides (Cinagene, Iran): 5'-CAT GCC ATG GCA TGG AAA AAG ATT AGC AGA AAA G-3' (forward) and 5'-CCG CTC GAG CGG GAA AAT GCT AAA GAG TTG CG-3' (reverse). The underlined bases designate *Nco*I and *Xho*I restriction sites. PCR was performed using Expand High Fidelity PCR System (Roche, Germany) following the manufacturer's protocol. PCR product fragment was electrophoresed on the 1% agarose gel stained with ethidium bromide. Subsequently the PCR product was purified using the DNA Extraction kit (MBI Fermentas, Lithuania) and double digested with *Nco*I and *Xho*I. The double digested PCR product was ligated into pET-26b(+), which was digested with the same restriction enzymes to form the over-expression plasmid pET26b-UreB. The ligated plasmids were transformed into the competent *E. coli* DH5α and transformants were selected on LB medium containing kanamycin (50 mg l⁻¹). The presence of inserts was confirmed by colony PCR. Correct orientation and the complete insert sequence were verified by restriction digestion analysis using *Pvu*I and sequencing (TAG Copenhagen, Denmark).

Expression of fusion protein

The pET26b-UreB transformed into the expression host *E. coli* BL21(DE3). To evaluate protein expression a single colony was inoculated into 10 ml of terrific broth containing kanamycin (50 mg l⁻¹) and grown at 37°C overnight. This preculture was then added to 500 ml of the same medium which was incubated on a shaker (200 rpm) at 37°C until the optical density (O.D. 600 nm) of culture reached up to 0.6. Bacterial cultures were induced using

different concentrations of isopropyl thiogalactoside (IPTG) 0.1–1.0 mM and the culture incubated in 22°C or 37°C. 1.5 ml bacterial culture was harvested every 1 h up to 8 h. Similarly, the *E. coli* BL21 containing pET-26b was induced up to 8 h as a negative control. Expression of protein was analyzed by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) under denaturing conditions. For purification of the recombinant protein, the *E. coli* culture was grown using the optimized expression conditions (Terrefic Broth medium, 22°C, 1 mM IPTG, 4 h of induction). The bacteria were harvested by centrifugation at 4°C.

Preparation of the periplasmic extract

Osmotic shock was applied according to the Neu and Heppel (1965), with modifications. Cell pellets were resuspended in ice-cold buffer A (0.03 M Tris–HCl, pH 7.3), and harvested by centrifugation at 5,000 rpm (5804R centrifuge, rotor # A-4-44, Eppendorf) for 10 min at 4°C. The pellets were suspended in 40 ml buffer A plus 40 ml ice-cold buffer B [0.3 M Tris–HCl pH 8.0, 1.5 mM EDTA, 40% (w/v) sucrose] for each gram wet weight of cells and was shaken for 30 min on ice. Following centrifugation, the pellet was rapidly resuspended in the same volume of cold water and the suspension shaken for 30 min on ice and then centrifuged again for 10 min. The supernatant (osmotic shock fluid) was collected as the periplasmic fraction.

Purification of recombinant UreB

Recombinant UreB was purified from the periplasm using a published protocol (Loo et al. 2002) with some modifications. Briefly, the periplasmic fraction was adjusted to pH 7 using Mops (Sigma, Germany) to produce a final concentration of 20 mM. The sample was then loaded onto a column containing 10 ml Ni-NTA agarose (nickel-nitrilotriacetic acid) (Qiagen, France), pre-equilibrated with chromatography buffer (20 mM Mops, 0.5 M NaCl, 5 mM imidazole, pH 8.0) and rocked for 3 h. The column was washed with chromatography buffer until the absorbance of the eluate returned to baseline. Recombinant UreB was eluted with a 20 ml 500 mM imidazole in chromatography buffer. Peak fractions were identified by SDS–PAGE. Positive fractions were pooled and dialyzed against PBS buffer at 4°C overnight. Protein concentration was measured by a Bradford assay based on a bovine serum albumin standard curve (Bradford 1976). To determine that periplasmic UreB was not contaminated by cytoplasmic proteins, presence of β -Galactosidase in osmotic shock and cytoplasmic fractions was compared. β -Galactosidase assays were performed using *o*-nitrophenyl- β -D-

galactopyranoside (ONPG) as a substrate, as described by Miller (1972).

SDS–PAGE and immunoblotting

The resulting bacterial pellet or purified protein were homogenized in SDS sample loading buffer [0.150 M Tris–Cl, pH 6.8; 10% glycerol; 2% SDS; 0.01% bromophenol blue; 0.5 M DTT (Dithiothreitol)]. It was mixed properly and boiled for 5 min and centrifuged at 11,000g for 2 min. Electrophoresis was performed in the presence of SDS according to the method of Laemmli (1970). The discontinuous gel consisted of a 5% stacking gel and a 10% separating gel which was run on a vertical electrophoresis unit (Mini-Protean II, BioRad). After SDS–PAGE gel was transferred onto nitrocellulose membrane by Bio-Rad Mini Trans-Blot Cell system following the procedure described. Membrane was blocked using 3% nonfat dry milk in TTBS (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Tween 20) for 1 h. Following four washes the membrane was dipped into 1:4,000 diluted monoclonal antibody conjugated peroxidase anti-His for 1.5 h at room temperature. BM Blue POD substrate precipitating (Roche, Germany) was used to develop the membrane, until dark purple bands appear, following the procedure described (Sambrook and Russell 2001).

Results

Construction of plasmid for periplasmic expression of UreB

To overcome problems associated with cytoplasmic expression of UreB (Evans et al. 1991; Icatlo et al. 1998; Lee et al. 1995), an expression vector for periplasmic expression of UreB was constructed. The full-length *ureB* gene without stop codon was amplified by primers which contains restriction sites. *NcoI* and *XhoI* restriction sites were introduced upstream and downstream of the *ureB* gene respectively, therefore the coding sequence was preceded by a *pelB* signal sequence at the 5' region and a 6His-tag at the 3' of the gene. The target fragment of *ureB* genes with the expected sizes are shown in Fig. 1.

Construct transformed into *E. coli* DH5- α cells and selected on LB containing kanamycin (50 mg l⁻¹). Transformants were characterized by colony PCR against *ureB* primers. The recombinant pET26b-UreB was extracted and its orientation confirmed by digestion with *PvuI* restriction enzyme. *PvuI* will have two restriction sites in recombinant plasmid, one in insert and the other one in vector. The two expected bands were observed on gel: a 1585–5442 bp bands (Fig. 2). Sequence analysis of




Fig. 1 Target amplification fragment of *ureB* gene and *NcoI* and *XhoI* double digested *ureB* PCR product. *Lane 1*, Lambda DNA/*EcoRI* + *HindIII* Marker; *Lane 2*, Target recovered fragment of *ureB* gene (1731 bp); *Lane 3*, Target recovered fragment *ureB* after digestion with both *NcoI* and *XhoI* (1722 bp)




Fig. 2 Agarose gel electrophoresis analysis of recombinant pET26b-UreB with *PvuI* restriction enzyme digestion. *Lane 1* Lambda DNA/*EcoRI*+*HindIII* Marker, *Lane 2* pET26b-UreB recombinant plasmid (white arrow, 7027 bp), *Lane 3* *PvuI* digested recombinant pET26b-UreB. Two expected fragments were observed on the gel (5442–1585 bp bands)

recombinant pET26b-UreB confirmed that there are no amplification errors and that cloning was accurate.

Overexpression and purification of *UreB*

The pET26b-UreB was transformed into the expression host *E. coli* BL21 (DE3). Transformant was grown at different temperatures, and expression was induced by IPTG and monitored by SDS-PAGE of total protein extracts




Fig. 3 SDS-PAGE analysis of the control negative bacteria (*E. coli* BL21 with pET21 without insert) (a) and the expressed UreB-6His tag protein in *E. coli* BL21 (b). A 15 μ l volume of each fractions were analyzed by 10% polyacrylamide gel. **a** *Lane 1*, PageRuler™ Unstained Protein Ladder; *lane 2*, total cell lysate of noninduced bacteria; *lane 3–6*, Total cell lysate of bacteria after 1–4 h induction; *lane 7*, total cell lysate of noninduced control negative *E. coli* BL21; *lane 8–10*, total cell lysate of induced control negative *E. coli* BL21 after 1–3 h induction **b** *Lane 1*, PageRuler™ Prestained Protein Ladder; *lane 2*, total cell lysate of noninduced bacteria; *lane 3*, Total cell lysate of bacteria after 4 h induction; *lane 4*, periplasmic proteins extracted by osmotic shock procedure; *lane 5*, purified periplasmic UreB-6His by Ni-NTA agarose. The arrow indicates the position of UreB-6His on the gel




Fig. 4 Western blot analysis of the expressed UreB-6His tag protein in *E. coli* BL21. A 15 μ l volume of each fractions were analyzed by 10% polyacrylamide gel and transferred onto nitrocellulose membranes and revealed with an anti-His monoclonal antibody. *Lane 1*, PageRuler™ Prestained Protein Ladder; *lane 2*, total cell lysate of noninduced bacteria; *lane 3*, Total cell lysate of bacteria after 4 h induction; *lane 4*, periplasmic proteins extracted by osmotic shock procedure; *lane 5*, purified periplasmic UreB-6His by Ni-NTA agarose. The arrow indicates the position of UreB-6His on the membrane

before and after induction. Highest levels of over-expressed UreB were obtained by allowing the bacterial cultures to grow to an OD₆₀₀ nm of 0.6–0.8 before induction and by inducing protein production for 4 h at 25°C with 1 mM IPTG. OD₆₀₀ at harvest was 5.0 and the cell wet weight after harvest was 4 g l⁻¹. The cell fractionation analysis showed that the UreB was mostly detected in the soluble fraction. Figures 3 and 4 show the protein profiles in non-induced and induced bacteria, periplasmic content and purified UreB-6His tag protein by Ni-NTA affinity

chromatography by SDS–PAGE and Western blot analyses. As shown in these figures a protein band migrating to the expected molecular weight for a UreB-6His-tag protein (≈ 65 kDa) was clearly detected in the induced cells after 4 h and periplasmic fraction extracted by osmotic shock procedure. The yield of purified UreB was about 0.5 mg l^{-1} of culture media.

To prevent release of cytoplasmic content into the periplasmic fraction during extraction (Malik et al. 2007), the purification procedure was carried out within one day at 4°C and in the presence of protease inhibitors. The small quantity of β -galactosidase activity detected in the recovery solutions from osmotic shock (less than 2% of cytoplasmic content) (data not shown) indicates that little cytoplasmic material is released by this procedure.

Discussion

Currently *H. pylori* is recognized as the most widespread human pathogen and approximately half of the world's population is infected (Czinn 2005; Rossi et al. 2004). There is great interest in developing a vaccination method to prevent *H. pylori* infection, given that immunization is always considered the most economic and efficient means for such prevention, especially in developing countries (Del Giudice and Michetti 2004; Rupnow et al. 1999).

The selection of antigenic targets is critical in the design of a *H. pylori* vaccine. A large number of published data showed that UreB might be the most definitive antigen candidate for *H. pylori* vaccine (Corthesy-Theulaz et al. 1995; Morihara et al. 2008; Pappo et al. 1995; Zhao et al. 2007). In order to simplify the procedure steps and further reduce cost in *H. pylori* vaccine production, the present report represents a novel method of producing recombinant urease subunit B extracellularly.

As *E. coli* does not naturally secrete high amounts of proteins (Sandkvist and Bagdasarian 1996), recovery of a recombinant gene product can be greatly simplified by a secretion strategy that minimises contamination from host proteins. Additionally, if the product is secreted to the culture medium, cell disruption is not required for recovery and even in the case of periplasmic translocation, a simple osmotic shock can be used to obtain the product without the release of cytoplasmic protein contaminants (Mergulhao et al. 2005; Shokri et al. 2003). The pET-26b vector produces recombinant protein with signal peptide pelB at the N-terminal for periplasmic secretion and a His-tag at the C-terminal for detection and purification. Therefore, *H. pylori* UreB has been cloned into pET-26b, which places protein over-expression under the control of a lac promoter that is inducible with IPTG. Recombinant UreB-6His has

been purified by using a single chromatography step. In this study the possibility of nonspecific exposure of cytoplasmic proteins has been ruled out by comparing periplasm β -gal activity to cytoplasm of *E. coli* transformed with pET26b-UreB-6His. The yield of purified UreB is lower than that in some cytosolic expression systems, however, considering the ease and low costs of scaling up a periplasmic procedure, the protocol can be regarded to be productive. In future the yield of the UreB protein could strongly be increased by use of different signal sequences of prokaryotic origin and optimizing the fermentation process. In conclusion, the present protocol is easier to perform; more time effective and low cost than earlier methods.

Acknowledgments This article has been extracted from an approved research (application No. U-870244) which has financially been supported by Research Deputy of Jundishapur University of Medical Sciences, Ahvaz, Iran. The authors would like to thank Mrs. Neisi and Mrs. Lotfi from Virology Department for assistance with this work, and Mrs. Noorbehbahani and Mrs. Amuzegari from Biochemistry Department of Jundishapur University of Medical Sciences, Ahvaz, Iran for their experience in chromatography throughout this study.

References

- Akada JK, Shirai M, Takeuchi H, Tsuda M, Nakazawa T (2000) Identification of the urease operon in *Helicobacter pylori* and its control by mRNA decay in response to pH. *Mol Microbiol* 36:1071–1084
- Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in *Escherichia coli*. *Nat Biotechnol* 22:1399–1408
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248–254
- Cornelis P (2000) Expressing genes in different *Escherichia coli* compartments. *Curr Opin Biotechnol* 11:450–454
- Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney AC, Haas R, Kraehenbuhl JP, Blum AL, Michetti P (1995) Oral immunization with *Helicobacter pylori* urease B subunit as a treatment against *Helicobacter* infection in mice. *Gastroenterology* 109:115–121
- Cuenca R, Blanchard TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK, Redline RW (1996) Therapeutic immunization against *Helicobacter mustelae* in naturally infected ferrets. *Gastroenterology* 110:1770–1775
- Czinn SJ (2005) *Helicobacter pylori* infection: detection, investigation, and management. *J Pediatr* 146:S21–S26
- Del Giudice G, Michetti P (2004) Inflammation, immunity and vaccines for *Helicobacter pylori*. *Helicobacter* 9(1):23–28
- Evans DJ Jr, Evans DG, Kirkpatrick SS, Graham DY (1991) Characterization of the *Helicobacter pylori* urease and purification of its subunits. *Microb Pathog* 10:15–26
- Ferrero RL, Thiberge JM, Huerre M, Labigne A (1994) Recombinant antigens prepared from the urease subunits of *Helicobacter* spp.: evidence of protection in a mouse model of gastric infection. *Infect Immun* 62:4981–4989
- Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A (1995) The GroES homolog of *Helicobacter pylori* confers protective immunity against mucosal infection in mice. *Proc Natl Acad Sci USA* 92:6499–6503

- Haas R, Meyer TF (1997) Vaccine development against *Helicobacter pylori* infections. *Biologicals* 25:175–177
- Hatzifoti C, Wren BW, Morrow WJ (2000) *Helicobacter pylori* vaccine strategies—triggering a gut reaction. *Immunol Today* 21:615–619
- Hatzifoti C, Bajaj-Elliott M, Dorrell N, Anyim M, Prentice MB, Nye KE, Wren B, Morrow WJ (2004) A plasmid immunization construct encoding urease B of *Helicobacter pylori* induces an antigen-specific antibody response and upregulates the expression of beta-defensins and IL-10 in the stomachs of immunized mice. *Vaccine* 22:2651–2659
- Icatlo FC Jr, Kuroki M, Kobayashi C, Yokoyama H, Ikemori Y, Hashi T, Kodama Y (1998) Affinity purification of *Helicobacter pylori* urease. Relevance to gastric mucin adherence by urease protein. *J Biol Chem* 273:18130–18138
- Labigne A, Cussac V, Courcoux P (1991) Shuttle cloning and nucleotide sequences of *Helicobacter pylori* genes responsible for urease activity. *J Bacteriol* 173:1920–1931
- Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680–685
- Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP (1995) Oral immunization with recombinant *Helicobacter pylori* urease induces secretory IgA antibodies and protects mice from challenge with *Helicobacter felis*. *J Infect Dis* 172:161–172
- Loo T, Patchett ML, Norris GE, Lott JS (2002) Using secretion to solve a solubility problem: high-yield expression in *Escherichia coli* and purification of the bacterial glycoamidase PNGase F. *Protein Expr Purif* 24:90–98
- Malik A, Jenzsch M, Lubbert A, Rudolph R, Sohling B (2007) Periplasmic production of native human proinsulin as a fusion to *E. coli* ecotin. *Protein Expr Purif* 55:100–111
- Mergulhao FJ, Summers DK, Monteiro GA (2005) Recombinant protein secretion in *Escherichia coli*. *Biotechnol Adv* 23:177–202
- Miller JH (1972) *Experiments in molecular genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- Moriyama F, Hifumi E, Yamada M, Nishizono A, Uda T (2008) Therapeutic effects of molecularly designed antigen UREB138 for mice infected with *Helicobacter pylori*. *Biotechnol Bioeng* 100:634–643
- Neu HC, Heppel LA (1965) The release of enzymes from *Escherichia coli* by osmotic shock and during the formation of spheroplasts. *J Biol Chem* 240:3685–3692
- Pappo J, Thomas WD Jr, Kabok Z, Taylor NS, Murphy JC, Fox JG (1995) Effect of oral immunization with recombinant urease on murine *Helicobacter felis* gastritis. *Infect Immun* 63:1246–1252
- Rastgar Jazii F, Karkhane AA, Yakhchali B, Fatemi SS, Deezagi A (2007) A simplified purification procedure for recombinant human granulocyte macrophage-colony stimulating factor from periplasmic space of *Escherichia coli*. *J Chromatogr B Analyt Technol Biomed Life Sci* 856:214–221
- Rossi G et al (2004) Therapeutic vaccination against *Helicobacter pylori* in the beagle dog experimental model: safety, immunogenicity, and efficacy. *Infect Immun* 72:3252–3259
- Rupnow MF, Owens DK, Shachter R, Parsonnet J (1999) *Helicobacter pylori* vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. *Helicobacter* 4:272–280
- Sambrook J, Russell DW (2001) *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- Sandkvist M, Bagdasarian M (1996) Secretion of recombinant proteins by gram-negative bacteria. *Curr Opin Biotechnol* 7:505–511
- Shokri A, Sanden AM, Larsson G (2003) Cell and process design for targeting of recombinant protein into the culture medium of *Escherichia coli*. *Appl Microbiol Biotechnol* 60:654–664
- Stadtlander CT, Gangemi JD, Khanolkar SS, Kitsos CM, Farris HE Jr, Fulton LK, Hill JE, Huntington FK, Lee CK, Monath TP (1996) Immunogenicity and safety of recombinant *Helicobacter pylori* urease in a nonhuman primate. *Dig Dis Sci* 41:1853–1862
- Turbett GR, Hoj PB, Horne R, Mee BJ (1992) Purification and characterization of the urease enzymes of *Helicobacter* species from humans and animals. *Infect Immun* 60:5259–5266
- NCBI. National Center for Biotechnology Information. Available from <http://www.ncbi.nlm.nih.gov/genbank>
- Zhao W, Wu W, Xu X (2007) Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against *H. pylori* infection in BALB/c mice. *Vaccine* 25:7664–7673